Please assess the completion status of the following clinical trial:

Trial Title: Study of Sitagliptin Treatment in Patients With Type 2 Diabetes During Ramadan (0431-263)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Muslim men and women with type 2 diabetes~* Participants who intend to fast during the month of Ramadan~* Participants who have been on a stable dose of sulfonylurea for at least three months~Exclusion Criteria:~* Participants with type 1 diabetes mellitus~* Pregnant or breast feeding women~* Participants with hypersensitivity or contraindication to dipeptidyl peptidase (DPP-4) treatment~* Participants on insulin~* Participants on any class of oral diabetic therapy other than sulfonylurea or metformin

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Sitagliptin (Type: EXPERIMENTAL): Sitagliptin 100 mg administered orally daily as monotherapy or in combination with metformin over the Ramadan period.
- Sulfonylurea (Type: ACTIVE_COMPARATOR): Sulfonylurea administered orally daily as monotherapy or in combination with metformin over the Ramadan period.

Based on this trial design, predict the completion outcome and termination type (if applicable).